GEN Exclusives

More »

GEN News Highlights

More »
Sep 6, 2011

CHDI and Galenea Ink Deal for Huntington Disease Research

  • Galenea will use its high-throughput synaptic transmission platform in a collaboration with CHDI Foundation intended to develop drugs that target the molecular underpinnings of cognitive and behavioral defects in Huntington disease (HD).

    Galenea and CHDI will look specifically at the mutant huntingtin protein. The collaboration will use Galenea’s two-pronged approach to identify and characterize the synaptic defects that occur in HD at both the neuronal and network levels.

    Galenea's platform consists of its Mantra™ (multiwell automated neuro transmission assay) system, a high-throughput screening assay that monitors synaptic events at the cellular level using primary neuronal cultures, as well as a system for establishing in vivo electroencephalography (EEG) measures of behaviors in rodent disease models by monitoring brain and behavioral activities.

    "We are excited to work with Galenea to determine whether EEG signatures in rodent HD models are reflective of the synaptic dysfunction seen in HD patients. Such information could significantly facilitate HD preclinical drug discovery efforts," adds George Yohrling, Ph.D., director, target assessment at CHDI.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Ill Patients Access to Experimental Medicines?

More »